Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MIN-101 phase 3 placebo-controlled monotherapy trial for negative symptoms of schizophrenia
MOH_2018-07-01_002485Phase 3Completed
- Sponsor
- Minerva Neurosciences, Inc.
- Start
- Apr 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of roluperidone in schizophrenia (4 arms), sponsored by Minerva Neurosciences, Inc. Primary endpoint: Efficacy of MIN-101 on negative symptoms of schizophrenia. Started Apr 2018; status: completed.
02
Drugs
roluperidone
03
Conditions
schizophrenia
Beyond the preview
Go deeper on MOH_2018-07-01_002485.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2018-07-01_002485.